{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:16:00Z","timestamp":1791036960741,"version":"4.1.0"},"reference-count":14,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.3892\/ol.2011.503","type":"journal-article","created":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T20:46:58Z","timestamp":1322772418000},"page":"269-272","source":"Crossref","is-referenced-by-count":4,"title":["Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation"],"prefix":"10.3892","volume":"3","author":[{"given":"TAKUMI","family":"OCHIAI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KAZUHIKO","family":"NISHIMURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TOMOO","family":"WATANABE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASAYUKI","family":"KITAJIMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AKINORI","family":"NAKATANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKASHI","family":"INOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIE","family":"WASHIO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NAOKI","family":"SAKUYAMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TSUYOSHI","family":"SATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KENJI","family":"KISHINE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKANORI","family":"OCHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SATOSHI","family":"OOKUBO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHUNJI","family":"FUTAGAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIDEKI","family":"ORIKASA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SATOMI","family":"MASHIKO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ISAO","family":"NAGAOKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2011,11,30]]},"reference":[{"key":"key20180108091454_b1-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.2010.1535","article-title":"Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab","volume":"304","author":"De Roock","year":"2010","journal-title":"JAMA"},{"key":"key20180108091454_b2-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/jco.2011.29.4_suppl.448","article-title":"Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p. G13D mutation treated with cetuximab","volume":"29","author":"Bando","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108091454_b3-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/jco.2011.29.15_suppl.3511","article-title":"Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab","volume":"29","author":"Tejpar","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108091454_b4-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2","article-title":"The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer","volume":"71","author":"Mayer","year":"1993","journal-title":"Cancer"},{"key":"key20180108091454_b5-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108091454_b6-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/jco.2007.25.18_suppl.4000","article-title":"Randomized phase III study of irinotecan and 5-FU\/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180108091454_b7-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1200\/jco.2011.29.4_suppl.407","article-title":"Japan Study Group of KRAS Mutation in Colorectal Cancer: Clinicopathological features in metastatic colorectal cancer patients with KRAS wild type compared with codon 12 and codon 13 mutant: Results from a multicenter, cross-sectional study by the Japan study group of KRAS mutation in colorectal cancer","volume":"29","author":"Yoshino","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108091454_b8-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/carcin\/bgg009","article-title":"K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study","volume":"24","author":"Brink","year":"2003","journal-title":"Carcinogenesis"},{"key":"key20180108091454_b9-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1046\/j.0007-1323.2001.01915.x","article-title":"Non-operative management of the primary tumor in patients with incurable stage IV colorectal cancer","volume":"88","author":"Sarela","year":"2001","journal-title":"Br J Surg"},{"key":"key20180108091454_b10-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1245\/s10434-006-9146-1","article-title":"Asymptomatic colorectal cancer with un-resectable liver metastasis: immediate colorectal resection or up-front systemic chemotherapy?","volume":"14","author":"Muratore","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"key20180108091454_b11-ol-03-02-0269","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/bjs.5346","article-title":"Neoadjuvant chemotherapy and resection of advanced synchronous liver metastasis before treatment of the colorectal primary","volume":"93","author":"Mentha","year":"2006","journal-title":"Br J Surg"},{"key":"key20180108091454_b12-ol-03-02-0269","first-page":"5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumorKRAS and BRAF mutation status","volume":"33","author":"Van Cutsem","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108091454_b13-ol-03-02-0269","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"key20180108091454_b14-ol-03-02-0269","first-page":"710","article-title":"KRAS status and efficacy in the Crystal study: 1st line treatment for patients with metastatic colorectal cancer receiving FOLFIRI with or without cetuximab","volume":"19","author":"Van Cutsem","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2011.503\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T03:39:18Z","timestamp":1593315558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2011.503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,30]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,11,30]]},"published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.3892\/ol.2011.503"],"URL":"https:\/\/doi.org\/10.3892\/ol.2011.503","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,30]]}}}